JYLAMVO
Clinical safety rating
cautionComprehensive clinical and safety monograph for JYLAMVO (JYLAMVO).
Comprehensive clinical and safety monograph for JYLAMVO (JYLAMVO).
Treatment of severe, active rheumatoid arthritis in adultsTreatment of polyarticular-course juvenile idiopathic arthritis in childrenTreatment of severe psoriasis in adults
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
| Metabolism | Methotrexate is primarily metabolized in the liver to polyglutamated forms, which are retained intracellularly. It undergoes hepatic metabolism via aldehyde oxidase and xanthine oxidase. Renal excretion is the major elimination route. |
| Excretion | Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%). |
| Half-life | Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 85-90% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.6-1.2 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is 60-75% due to first-pass metabolism; absolute bioavailability is 70%. |
| Onset of Action | Oral: Peak plasma concentration reached 2-4 hours post-dose; clinical effect begins within 4-6 hours. Intravenous: Onset within 30-60 minutes. |
| Duration of Action | Duration of therapeutic effect is approximately 12-24 hours after oral administration, correlating with half-life; extended duration in renal impairment requires dose adjustment. |
| Molecular Weight | 558.62 |
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment is recommended for patients with mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl 15-29 mL/min), reduce dose to 20 mg twice daily. For end-stage renal disease (CrCl <15 mL/min) or on dialysis, not recommended due to lack of data. |
| Liver impairment | For patients with mild hepatic impairment (Child-Pugh A), no dose adjustment. For moderate hepatic impairment (Child-Pugh B), reduce dose to 20 mg twice daily. For severe hepatic impairment (Child-Pugh C), not recommended. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no recommended dosage. |
| Geriatric use | No specific dose adjustment required based on age alone; monitor for increased risk of adverse events (e.g., myelosuppression, infections) as elderly patients may have decreased organ function and comorbidities. |
| 1st trimester | Avoid. Contraindicated due to high risk of fetal malformations (neural tube defects, cardiovascular anomalies). |
| 2nd trimester | Avoid. Continued risk of adverse fetal effects. |
| 3rd trimester | Avoid. May cause neonatal hemorrhage and maternal hepatotoxicity. |
Clinical note
Comprehensive clinical and safety monograph for JYLAMVO (JYLAMVO).
| Placental transfer | Extensive placental transfer; crosses the placenta readily as demonstrated in animal studies and human placental perfusion models. |
| Breastfeeding | Contraindicated during breastfeeding. JYLAMVO is excreted into breast milk and may cause serious adverse effects in the nursing infant, including bone marrow suppression and immunosuppression. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | JYLAMVO (methotrexate) is contraindicated in pregnancy. It is an abortifacient and teratogen. First trimester exposure causes multiple congenital anomalies (craniofacial, limb, CNS defects) and spontaneous abortion. Second and third trimester use may cause fetal growth restriction, developmental delay, and potential methotrexate syndrome. Use effective contraception during and for at least 3 months after treatment. |
| Fetal Monitoring | Monitor complete blood count, liver and renal function tests weekly during first month, then monthly. Assess for signs of myelosuppression, hepatotoxicity, and pulmonary toxicity. In pregnant patients (if exposure occurs), obtain high-resolution ultrasound and fetal echocardiography. Serial growth scans for potential intrauterine growth restriction. |
| Fertility Effects | Methotrexate can impair fertility in both males and females. In males, may cause oligospermia and reversible infertility. In females, may cause menstrual dysfunction and ovarian failure; effects are usually reversible upon discontinuation. Contraception counseling is required. |
■ FDA Black Box Warning
JYLAMVO can cause severe or fatal toxicities including hepatotoxicity, myelosuppression, pulmonary fibrosis, and renal failure. It is contraindicated in pregnancy (teratogenic) and in nursing mothers. Fatal toxicity has been reported with concomitant NSAID use. Monitoring for toxicity and appropriate dosing adjustments are required.
| Serious Effects |
PregnancyBreastfeedingSevere hepatic impairmentSevere renal impairment (CrCl <30 mL/min)Hypersensitivity to JYLAMVO or any componentActive serious infection
| Precautions | Hepatotoxicity (monitor liver function), myelosuppression (monitor CBC), pulmonary toxicity (interstitial pneumonitis), renal toxicity (monitor renal function), gastrointestinal toxicity, neurotoxicity, infections, and tumor lysis syndrome. Corticosteroids or other immunosuppressants may increase risk of infection. |
| Food/Dietary | No specific food interactions are known. Administer without regard to meals. Maintain adequate hydration. |
| Clinical Pearls | JYLAMVO (amivantamab) is a bispecific EGFR-MET antibody for EGFR exon 20 insertion mutation-positive NSCLC. Monitor for infusion-related reactions (premedicate with antihistamines, antipyretics, and corticosteroids). Assess for interstitial lung disease (ILD) prior to each dose; withhold for suspected ILD. Check serum albumin and electrolytes before treatment; hypoalbuminemia increases risk of toxicities. Advise use of sunscreen and sun protective measures due to photosensitivity risk. |
| Patient Advice | JYLAMVO is given as an intravenous infusion over 2-4 hours, typically every 2 weeks after an initial loading dose. · You may experience infusion reactions; symptoms include fever, chills, nausea, or shortness of breath. Tell your nurse immediately if these occur. · This drug can cause lung inflammation (ILD); report any new or worsening cough, chest pain, or difficulty breathing. · Avoid prolonged sun exposure; use broad-spectrum sunscreen (SPF 30+) and wear protective clothing. · Your doctor will monitor your blood counts and kidney function regularly during treatment. |
Loading safety data…